The Parkinson’s Foundation has announced an investment of over $4.3 million to fund 44 grants aimed at accelerating innovative research on Parkinson’s disease (PD). These grants support scientists exploring various aspects of PD with the goal of developing new therapies, improving treatments, and ultimately finding a cure for the 10 million people worldwide affected by the disease.
John Lehr, President and CEO of the Parkinson’s Foundation, highlighted that this year’s research grant cohort is larger than ever, enabling a broader range of scientific inquiry into the complex mechanisms of PD. The initiative reflects the Foundation’s commitment to driving progress toward better therapies and a cure.
Among the grant recipients is Jeff Kim, PhD, from Baylor College of Medicine, who will use artificial intelligence (AI) models to investigate the complexities of PD genetics. His research will examine how combinations of different genetic mutations may influence the likelihood of developing PD and identify previously overlooked mutations. These findings could then be tested in fruit flies to observe whether they produce Parkinson’s-like symptoms, potentially guiding the development of novel therapeutics.
Dr. Kim explained that his project addresses the interplay between rare gene mutations and common genetic variations and how these interactions may change with age. The research aims to generate clinically useful genetic information that could lead to personalized treatment strategies for people with Parkinson’s disease.
The Parkinson’s Foundation selects research grants through a rigorous, competitive process that involves peer review by scientific experts and Foundation-trained research advocates. Grant categories include independent investigator awards, fellowships, and early career awards.
James Beck, PhD, Chief Scientific Officer of the Parkinson’s Foundation, emphasized the role of innovative approaches, including AI, in advancing Parkinson’s research. He noted that the exponential growth of technology increases the potential for accelerated discoveries, reinforcing the Foundation’s hope for significant progress in understanding and treating PD.
